Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Assisted Reproductive Technology Clinical criteria: The treatment must be for prevention of premature luteinisation and ovulation, AND Patient must be undergoing controlled ovarian stimulation, AND Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.
Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate Clinical criteria: Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Central precocious puberty Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by a paediatric endocrinologist; OR Must be treated by an endocrinologist specialising in paediatrics. Population criteria: Patient must be of an age that is prior to their 12th birthday if female; OR Patient must be of an age that is prior to their 13th birthday if male, AND Patient must have had onset of signs/symptoms of central precocious puberty prior to their 9th birthday if female; OR Patient must have had onset of signs/symptoms of central precocious puberty prior to their 10th birthday if male.
“Triptorelin, a gonadotropin releasing hormone (GnRH) agonist, inhibits gonadotropin secretion when given continuously and in therapeutic doses.”
“The mean terminal half-life was 5.1 (range: 2.5 to 13.8) hours.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.